

Neurotech

3 September 2020

Neurotech secures a new European commercial agreement with Brain Therapeutics in Greece as Mente Autism therapy distribution partner

Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, is pleased to announce that it has secured Brain Therapeutics, a specialist in CNS products for the Greek market.

With many years of experience bringing premium products, services and support to the healthcare market in Greece and 12 more countries (66 million population), Brain Therapeutics is a central nervous system specialty company focused on three therapeutic areas: psychiatry, neurology and pain. Brain Therapeutics is focused on the high unmet need in the sophisticated area of CNS and the team has collectively more than 100 years’ experience within brain disorders, along with commercial capabilities acquired through years of experience in multinational pharma. In addition, the team has a strong network among CNS key opinion leaders.

Brain Therapeutics personnel are being introduced to Mente shortly and an initial marketing plan for Mente Autism is being prepared. An autism breakthrough, clinically proven Mente helps ASD children to learn to engage positively with their environment. Mente is the world’s only personalised neurofeedback therapy clinically proven to help children with ASD self-regulate attention and mood. Mente is available through <https://www.mentetech.com/>

Peter Griffiths, CEO of Neurotech International said: “We are delighted to announce Brain Therapeutics as our distribution partner in Greece. After successfully renewing our CE Medical registration, this is another milestone for Neurotech in Europe. Brain Therapeutics has extensive experience and commercial capabilities in Greece and other regions such as Balkan countries & Eastern Europe, we look forward to working with them to market and promote Mente Autism.”

George Pavlakis, Managing Director of Brain Therapeutics, said: “We are honoured to have been chosen to represent Neurotech in Greece. Our experience in the field coupled with Neurotech’s vision for autism will allow us to tap into what we believe is an outstanding market potential.”

More information on Brain Therapeutics can be obtained from their website <http://www.braintherapeutics.gr/>

This announcement has been authorised for release by the Board of Directors of the Company.

For further information, please contact:

Peter Griffiths
CEO & Managing Director
peter.griffiths@mentetech.com

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Neurotech International Ltd
ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mentetech please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

www.neurotechinternational.com